Lazard Asset Management
CERE

Lazard Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Lazard Asset Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,336
Closed -$233K – 2523
2023
Q2 		$233K Sell
7,336
-744
-9% -$22.8K ﹤0.01% 1305
2023
Q1 		$197K Sell
8,080
-2,078
-20% -$61K ﹤0.01% 1316
2022
Q4 		$320K Buy
+10,158
New +$287K ﹤0.01% 1199

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lazard Asset Management's CERE Position: Q3 2023 in Review

Lazard Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2023, closing a stake of 7,336 shares — an estimated $233K sold.

Lazard Asset Management first reported a position in CERE in Q4 2022 and held it in 3 quarters. The position peaked at $320K in Q4 2022. 119 funds tracked by Wall St. Rank hold CERE as of Q3 2023.

  • Lazard Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Lazard Asset Management sold 7,336 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2023, an estimated $233K.
  • Lazard Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • Lazard Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $320K in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2023.

Based on Lazard Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.